A Phase 3b, Randomized, Open-label, Multi-Center Study Assessing Immunogenicity, Safety and 1 Year Persistence of Antibodies after One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine, administered to Healthy Children 2 to 10 years of age [III.b. fazisu, randomizalt, nyilt, multicentrikus vizsgalat az immunogenitas, a biztonsagossag es az ellenanyagok 1 eves perzisztenciajanak ertekelesere, egy vagy ket adag Novartis Meningococcus ACWY konjugalt oltoanyag, 2-10 eves egeszseges gyermekeknel torten? alkalmazasa utan]

Trial Profile

A Phase 3b, Randomized, Open-label, Multi-Center Study Assessing Immunogenicity, Safety and 1 Year Persistence of Antibodies after One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine, administered to Healthy Children 2 to 10 years of age [III.b. fazisu, randomizalt, nyilt, multicentrikus vizsgalat az immunogenitas, a biztonsagossag es az ellenanyagok 1 eves perzisztenciajanak ertekelesere, egy vagy ket adag Novartis Meningococcus ACWY konjugalt oltoanyag, 2-10 eves egeszseges gyermekeknel torten? alkalmazasa utan]

Recruiting
Phase of Trial: Phase III

Latest Information Update: 23 Oct 2012

At a glance

  • Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
  • Indications Meningococcal group A infections; Meningococcal group B infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Novartis Vaccines
  • Most Recent Events

    • 30 Mar 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top